MiMedx to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call on March 9

Rhea-AI Summary

MiMedx Group, Inc. (Nasdaq: MDXG) announced it will report its financial results for the fourth quarter and full year ended December 31, 2020, after market close on March 8, 2021. A conference call and webcast will be held on March 9, 2021, at 9:30 AM ET with key executives discussing the results. MiMedx specializes in advanced wound care and therapeutic biologics, focusing on the development of human placental tissue allografts. They have distributed over two million allografts using their proprietary PURION process.

Positive

• Scheduled financial results release on March 8, 2021 will provide insights into company performance.
• Webcast and conference call offer transparency and engagement with investors.

Negative

• None.

MARIETTA, Ga., March 02, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2020 after the market close on Monday, March 8, 2021. MiMedx management will host a webcast and conference call to review its results on Tuesday, March 9, 2021, beginning at 9:30 am, Eastern Time. Participating on the call will be Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development.

This conference call can be accessed using the following information:

Webcast: https://edge.media-server.com/mmc/p/outonjvn
U.S. Investors: 877-359-9508
International Investors: 224-357-2393
Conference ID: 4786292

A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event.

About MiMedx
MiMedx^® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION^® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied more than two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contacts:
Investors
Jack Howarth
404-360-5681
investorrelations@mimedx.com

 

FAQ

When will MiMedx report its Q4 and full year 2020 financial results?

MiMedx will report its financial results on March 8, 2021, after market close.

What is the significance of the upcoming MI Medx conference call?

The conference call on March 9, 2021, will allow management to discuss financial results and engage with investors.

Where can I access the MiMedx financial results webcast?

The webcast can be accessed through MiMedx's investor relations page or via the link provided in the press release.

What is MiMedx known for?

MiMedx is known for its advanced wound care products and the development of human placental tissue allografts.